Abstract
BackgroundFilgotinib (FIL), a preferential Janus Kinase (JAK) inhibitor targeting the JAK1 enzyme, has demonstrated efficacy in rheumatoid arthritis (RA) in clinical trials. FIL is reimbursed in Belgium since August 2021...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have